Epizyme (EPZM) Tops Q3 EPS by 3c

Epizyme (NASDAQ: EPZM) reported Q3 EPS of ($0.56), $0.03 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $358 thousand versus the consensus estimate of $5.42 million.

For earnings history and earnings-related data on Epizyme (EPZM) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Barclays Upgrades Allegro (AL0:GR) to Overweight
• Nucor projects Q3 2026 earnings above prior year, below estimates